Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25905202 | 0.93 | AR (0.71) | ARSMN1; SMN2HTTNPSR1GPR119 | |
| SCHEMBL24031638 | 0.89 | AR (0.63) | ARGPR119HDAC4 | |
| SCHEMBL26802787 | 0.89 | AR (0.74) | AR | |
| SCHEMBL24193167 | 0.86 | AR (0.59) | ARSMN1; SMN2HTTNPSR1GPR119 | |
| SCHEMBL30893441 | 0.85 | AR (0.56) | AR | |
| SCHEMBL24031880 | 0.85 | AR (0.82) | AR | |
| SCHEMBL20046688 | 0.84 | AR (0.78) | ARSMN1; SMN2HTTNPSR1GPR119 | |
| SCHEMBL24031884 | 0.83 | AR (0.80) | AR | |
| SCHEMBL30893503 | 0.83 | AR (0.54) | AR | |
| SCHEMBL24031878 | 0.83 | AR (0.80) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2022011205-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2021231927-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | AR 1/4885SMN1; SMN2 2044/4885HTT 2645/4885 |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | AR 1/4885SMN1; SMN2 2965/4885HTT 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.